CSIMarket Company Name, Ticker, Customers, else..
 
Spero Therapeutics Inc   (NASDAQ: SPRO)
Other Ticker:  
 
 

Spero Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information



SPRO Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) -47.12 % 9.72 % 7.32 % 4.04 %
Q / Q Revenue Growth (Q3 MRQ) 32.09 % 3.93 % 2.74 % 0.38 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 37.01 % 2.21 % 5.37 % %
Seq. Revenue Growth (for 12 months ending Q3 TTM) -10.13 % 2.56 % 1.78 % 1.13 %
Revenue 5 Year Average Growth 92.11 % 8.81 % 8.02 % 7.61 %


SPRO's Growth Comparisons in III. Quarter 2024




As Spero Therapeutics Inc 's sales faded by -47.12% year on year in the third quarter 2024, the Major Pharmaceutical Preparations industry grew by 9.72%, Spero Therapeutics Inc 's third quarter 2024 performance was trailing the Major Pharmaceutical Preparations industry in the third quarter 2024, and underperformed the 7.32% Revenue growth in the Healthcare sector. Although both Major Pharmaceutical Preparations industry and Healthcare sector posted higher gains than 4.04% overall market increase, Spero Therapeutics Inc was trailing overall market in the third quarter.

Company's sequential top-line increase was 32.09% from the second quarter. Average annual sales rise for Spero Therapeutics Inc is 92.11%, while S & P 500's average yearly sales growth is 7.61% over the five years, including only Businesses with the third quarter 2024 Results.

SPRO Growth Rates by Company's Segments

Segment Name
Y / Y
Seq.
Total
-47.12 %
32.09 %


Growth Rates of SPRO's Income in the third quarter 2024


SPRO Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 90.01 % 79.87 % 4.47 %
Seq. Operating Income Change (Q3 MRQ) - 42 % 32.89 % -2.32 %
Y / Y Operating Income Growth (Q3 TTM) - -32 % -6.27 % 9.43 %
Seq. Operating Income Growth (Q3 TTM) - 29.21 % 19.57 % 1.41 %
Operating Income 5 Year Avg. Change - 3.06 % 6.12 % 9.14 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - 163.9 % 300.33 % -1.46 %
Seq. Income from Cont. Ops. Change (Q3 MRQ) - 59.69 % 118.97 % -8.78 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - -0.92 % 25.4 % 9.03 %
Seq. Income from Cont. Ops. Change (Q3 TTM) -79.87 % 41.96 % 56.17 % -0.03 %
Income from Cont. Ops. 5 Year Avg. Change - -3.62 % -9.72 % 7.31 %

SPRO Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - -38.82 % 7.68 % -6.26 %
Q / Q Net Income Growth (Q3 MRQ) - 59.47 % 132.77 % -6.77 %
Y / Y Net Income Change (Q3 TTM) - -40.61 % -11.87 % 5.37 %
Seq. Net Income Change (Q3 TTM) -79.87 % -25.75 % 1.79 % -1.38 %
Net Income 5 Year Avg. Growth - 4.44 % -3.38 % 7.45 %

SPRO's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - 159.97 % 300.33 % -1.46 %
Seq. EPS from Cont. Ops. Change (Q3 MRQ) - 58.62 % 118.97 % -8.78 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) 876.71 % - - -
Seq. EPS from Cont. Ops. Change (Q3 TTM) -77.43 % - - -6.57 %
EPS from Cont. Ops. 5 Year Avg. Growth - -16.63 % -9.72 % 7.31 %



SPRO EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - -39.73 % 7.68 % -6.26 %
Q / Q EPS Net Growth (Q3 MRQ) - 58.4 % 132.77 % -6.77 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 44.84 %
Seq. EPS Net Change (for 12 months ending Q3 TTM) - - - -6.16 %
EPS Net 5 Year Avg. Change - 4.44 % -3.38 % 7.45 %



Spero Therapeutics Inc reported bottom-line of $ -0.32 in the third quarter, compare to $ -0.06 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -39.73%, while Healthcare sector increased by 7.68%, and overall market declined by -6.26%.

The company's sequential bottom-line increase was 32.09% from the second quarter. Average annual income per share rise for Spero Therapeutics Inc is 92.11%, while S & P 500's average yearly income per share growth is 7.45% over the five years, including only Businesses with the third quarter 2024 earnings results.

SPRO Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) -19.81 % 38.13 % 38.1 % -42.77 %
Seq. Free Cash Flow Change (Q3 MRQ) - 201.39 % 108.77 % -36.66 %
Y / Y Free Cash Flow Change (Q3 TTM) - 0.93 % 5.04 % 3.53 %
Seq. Free Cash Flow Change (Q3 TTM) - 8.08 % 8.08 % -10.84 %
Free Cash Flow 5 Year Avg. Change - 11.97 % 7 % 11.94 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) -20.9 % - -73.85 % -
Seq. Net Cash Flow Change (Q3 MRQ) - - - -
Y / Y Net Cash Flow Change (Q3 TTM) - - - -
Seq. Net Cash Flow Change (Q3 TTM) - - - -
Net Cash Flow 5 Year Avg. Change - 1.43 % 11.17 % -33.53 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) - 2.06 % 1.58 % 2.82 %
Seq. Capital Expenditures Change (Q3 MRQ) - 9.66 % 5.47 % 2.92 %
Y / Y Capital Expenditures Change (Q3 TTM) - 5.82 % 3.94 % 70.82 %
Seq. Capital Expenditures Change (Q3 TTM) - 1.69 % 2.08 % -0.52 %
Capital Expenditures 5 Year Avg. Change - 13.67 % 9.35 % 8.99 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com